var data={"title":"Activated charcoal: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Activated charcoal: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5864?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=activated-charcoal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Activated charcoal: Patient drug information&quot;</a> and <a href=\"topic.htm?path=activated-charcoal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Activated charcoal: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149199\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actidose-Aqua [OTC];</li>\n      <li>Actidose/Sorbitol [OTC];</li>\n      <li>Char-Flo with Sorbitol [OTC];</li>\n      <li>EZ Char [OTC];</li>\n      <li>Kerr Insta-Char in Sorbitol [OTC];</li>\n      <li>Kerr Insta-Char [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149200\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Charac-25 [OTC];</li>\n      <li>Charac-50 [OTC];</li>\n      <li>Charactol-25 [OTC];</li>\n      <li>Charactol-50 [OTC];</li>\n      <li>Charcodote Susp [OTC];</li>\n      <li>Charcodote TFS [OTC];</li>\n      <li>Charcodote-Aqueous Sus;</li>\n      <li>Premium Activated Charcoal [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149214\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149202\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute poisoning:</b> Oral, NG: <b>Note:</b> Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is <b>not</b> recommended due to the potential risk of severe dehydration and electrolyte imbalance. Some clinicians still recommend dosing activated charcoal in a 10:1 (charcoal:poison) ratio for optimal efficacy (Gude 2009); however, the amount of poison ingested is commonly unknown, which makes this approach challenging and often impractical (Chyka 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single dose (Chyka 2005): 25 to 100 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multidose: Initial dose: 50 to 100 g followed by 25 to 50 g every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial hemorrhage associated with oral <i>non-</i>vitamin K antagonist anticoagulants (off-label use): </b>Oral, enteral: 50 g within 2 hours of ingestion of an oral direct thrombin inhibitor (dabigatran) or an oral direct factor Xa inhibitor (eg, apixaban, edoxaban, or rivaroxaban). Concomitant agents are also recommended in certain patients (ie, 4-factor prothrombin complex concentrate [PCC] or activated PCC [aPCC] for direct factor Xa inhibitor reversal <b>or</b> idarucizumab for dabigatran reversal) (NCS/SCCM [Frontera 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149210\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=activated-charcoal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Activated charcoal: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute poisoning: </b>Oral, NG: <b>Note:</b> Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is <b>not</b> recommended due to the potential risk of severe dehydration and electrolyte imbalance, especially in children. Some clinicians still recommend dosing activated charcoal in a 10:1 (charcoal:poison) ratio for optimal efficacy (Gude 2009); however, the amount of poison ingested is commonly unknown, which makes this approach challenging and often impractical (Chyka 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single dose (Chyka 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &lt;1 year: 10 to 25 g; <b>Note:</b> Although dosing by body weight is reported in children (0.5 to 1 g/kg) and published in many resources, there are no data or scientific rationale to support this recommendation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 12 years: 25 to 50 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;12 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multidose: Initial dose: 25 to 50 g; followed by multiple doses of 10 to 25 g every 4 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149203\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149185\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actidose-Aqua: 15 g/72 mL (72 mL); 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [sweet flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actidose/Sorbitol: 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [sweet flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kerr Insta-Char: 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [contains fd&amp;c red #40, methylparaben sodium, propylene glycol, propylparaben sodium, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kerr Insta-Char: 50 g/240 mL (240 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kerr Insta-Char in Sorbitol: 25 g/120 mL (120 mL); 50 g/240 mL (240 mL) [contains fd&amp;c red #40, methylparaben sodium, propylene glycol, propylparaben sodium, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Char-Flo with Sorbitol: 25 g (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EZ Char: 25 g (1 ea) [contains bentonite]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149172\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149187\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Flavoring agents (eg, chocolate syrup, concentrated fruit juice) or thickening agents (eg, bentonite, carboxymethylcellulose) can enhance charcoal's palatability; however, they may interfere with the ability of activated charcoal to adsorb poisons. Check for the presence of bowel sounds before administration. IV antiemetics may be required to reduce the risk of vomiting. The activated charcoal container should be agitated thoroughly before administration. The container should be rinsed with a small quantity of water to insure that the patient has received all of the activated charcoal (Krenzelok 1991).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Capsules and tablets should not be used for the treatment of poisoning.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149186\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Activated charcoal is a nonabsorbable adsorbent that may be considered in the management of poisonings when gastrointestinal decontamination of drugs or chemicals is indicated (eg, presentation to a treatment facility within 1 hour of ingestion; but use beyond 1 hour is not contraindicated). Activated charcoal is generally an effective adsorbent of drugs and chemicals with a molecular weight range of 100 to 1,000 daltons. Multidose activated charcoal may be considered if a patient has ingested a life-threatening amount of carbamazepine, dapsone, phenobarbital, quinine, or theophylline (Vale 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules, tablets: Digestive aid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50015723\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Intracranial hemorrhage associated with oral non-vitamin K antagonist anticoagulants</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149220\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Actidose may be confused with Actos</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149179\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distention, appendicitis, constipation, dental discoloration (black; temporary), fecal discoloration (black), intestinal obstruction, mouth discoloration (black; temporary), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Corneal abrasion (with direct contact)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Aspiration, respiratory failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149190\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no absolute contraindications listed within the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> The American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) consider the following to be contraindications to the use of charcoal  (Chyka 2005; Vale 1999): Presence of intestinal obstruction or GI tract not anatomically intact; patients at risk of GI hemorrhage or perforation; patients with an unprotected airway (eg, CNS depression without intubation); if use would increase the risk and severity of aspiration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149176\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vomiting: Charcoal may cause vomiting; the risk appears to be greater when charcoal is administered with sorbitol (Chyka 2005). IV antiemetics may be required to reduce the risk of vomiting or to control vomiting to facilitate administration (Vale 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Decreased peristalsis: Use with caution in patients with decreased peristalsis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ipecac: Ipecac should not be administered routinely in the management of poisoned patients (AACT 2004b). In addition, use may delay the administration of or decrease the effectiveness of activated charcoal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cathartics (eg, sorbitol, mannitol, magnesium sulfate): Coadministration of a cathartic is <b>not</b> recommended; cathartics have not been demonstrated to change patient outcome and have no role in the management of the poisoned patient. Cathartics subject the patient to the risk of developing significant fluid and electrolyte abnormalities (AACT 2004a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Capsules: Not recommended for use in the treatment of poisoning.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sorbitol: Some products may contain sorbitol; coadministration of a cathartic, including sorbitol, is <b>not</b> recommended. Do not use products containing sorbitol in patients with a genetic intolerance to fructose or in patients who are dehydrated; may cause excessive diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablets: Not recommended for use in the treatment of poisoning.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Not effective in the treatment of poisonings due to the ingestion of low molecular weight compounds such as cyanide, iron, ethanol, methanol, or lithium. Avoid use in hydrocarbon and caustic ingestions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Efficacy: Most effective when administered within 30-60 minutes of ingestion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multidose administration: Based on experimental and clinical studies, multidose activated charcoal, in most acute poisonings, has not been shown to reduce morbidity or mortality (Vale 1999). It may be considered if a patient has ingested a life-threatening amount of carbamazepine, dapsone, phenobarbital, phenytoin, quinine, or theophylline, although no controlled studies have demonstrated clinical benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299010\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149180\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9237&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Charcoal, Activated may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to charcoal when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: Charcoal, Activated may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to charcoal when possible. Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149196\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">The addition of some flavoring agents (eg, milk, ice cream, sherbet, marmalade) are known to reduce the adsorptive capacity, and therefore the efficacy, of activated charcoal and should be avoided in preference to activated charcoal-water slurries; nevertheless, these flavoring agents do not completely compromise the effectiveness of activated charcoal and may be necessary in some circumstances (eg, administration in pediatric patients) to enhance compliance (Cooney 1995; Dagnone 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13657798\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Activated charcoal is not absorbed systemically following oral administration. Use during pregnancy is not expected to result in significant exposure to the fetus. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13658389\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Activated charcoal is not absorbed systemically following oral administration. Breast-feeding is not expected to result in significant exposure to a nursing child.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149175\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Adsorbs toxic substances, thus inhibiting GI absorption and preventing systemic toxicity.  Administration of multiple doses of charcoal may interrupt enteroenteric, enterohepatic, and enterogastric circulation of some drugs; may also adsorb any unabsorbed drug which remains in the gut.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149189\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In studies using adult human volunteers: Mean <b>reduction</b> in drug absorption following a single dose of &ge;50 g activated charcoal (AACT [Chyka 2005]): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given within 30 minutes after ingestion: 47.3% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 60 minutes after ingestion: 40.07% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 120 minutes after ingestion: 16.5% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 180 minutes after ingestion: 21.13% reduction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Given at 240 minutes after ingestion: 32.5% reduction </p>\n    <p style=\"text-indent:0em;\">Absorption: Not absorbed from the GI tract </p>\n    <p style=\"text-indent:0em;\">Excretion: Feces (as charcoal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323056\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Kerr Insta-Char in Sorbitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 g/120 mL (120 mL): $29.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 g/240 ml (240 mL): $40.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Kerr Insta-Char Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 g/120 mL (120 mL): $29.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 g/240 ml (240 mL): $40.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Char-Flo with Sorbitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-48 g/120 mL (120 mL): $6.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149192\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acticarb (AE, EG);</li>\n      <li>Antipois (VN);</li>\n      <li>Bekarbon (ID);</li>\n      <li>Biocarbon (AT, MT, MY);</li>\n      <li>Ca-R-Bon (TH);</li>\n      <li>Carbo Medicinalis (PL);</li>\n      <li>Carbomint (VN);</li>\n      <li>Carbomix (DK, FR, MT, SE, TR, TW);</li>\n      <li>Carbon Natural (UY);</li>\n      <li>Carbosorb (CZ, NZ);</li>\n      <li>Carbosorb X (AU, NZ);</li>\n      <li>Carbosorb XS (AU, NZ);</li>\n      <li>Carbotox (SK);</li>\n      <li>Carbotural (MX);</li>\n      <li>Charcodote (GB, KR, SG);</li>\n      <li>Charcotrace (AU, KR);</li>\n      <li>Deltacarbon (TH);</li>\n      <li>Eucarbon (QA);</li>\n      <li>JL Bragg's Medicinal Charcoal (HK);</li>\n      <li>Karbosorb (HU);</li>\n      <li>Koal (BD);</li>\n      <li>Kremezin (TW);</li>\n      <li>Mamograf (AR);</li>\n      <li>Neocarbon (BR);</li>\n      <li>Norit (IL);</li>\n      <li>RCOL (IN);</li>\n      <li>Ultra Carbon (AE, CY, EG);</li>\n      <li>Ultracarbon (MY, SG, TR);</li>\n      <li>Yo'Come Penney (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alasp&auml;&auml; AO, Kusima MJ, Hoppu K, et al, &ldquo;Feasibility Study on Activated Charcoal Given Prehospital by Emergency Medical System (EMS) in Acute Intoxications,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2002, 40(3):312-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), &quot;Position Paper: Cathartics,&quot; <i>J Toxicol Clin Toxicol</i>, 2004a, 42(3):243-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/15362590/pubmed\" target=\"_blank\" id=\"15362590\">15362590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), &quot;Position Paper: Ipecac Syrup,&quot; <i>J Toxicol Clin Toxicol</i>, 2004b, 42(2):133-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/15214617/pubmed\" target=\"_blank\" id=\"15214617\">15214617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bond GR, &quot;The Role of Activated Charcoal and Gastric Emptying in Gastrointestinal Decontamination: A State-of-the-Art Review,&quot; <i>Ann Emerg Med</i>, 2002, 39(3):273-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/11867980/pubmed\" target=\"_blank\" id=\"11867980\">11867980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Christophersen AB, Hoegberg LC, Angelo HR, et al, &ldquo;Activated Charcoal in a Simulated Paracetamol Overdose: Downscaling of Dose to 10 Grams - Preliminary Results,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2002, 40(5):696.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chyka PA, Seger D, Krenzelok EP, et al, American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists, &ldquo;Position Paper: Single-Dose Activated Charcoal,&rdquo; <i>Clin Toxicol (Phila)</i>, 2005, 43(2):61-87 (review).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooney DO, &ldquo;Development of Palatable Formulations,&rdquo; <i>Activated Charcoal in Medical Applications</i>, Cooney DO, ed, New York, NY: Marcel Dekker, Inc, 1995, 397-417.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper GM, Le Coteur DG, Richardson DB, et al, &ldquo;A Randomized Clinical Trial of Activated Charcoal for the Routine Management of Oral Drug Overdose,&rdquo; <i>Acad Emerg Med</i>, 2002, 9(5):487.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dagnone D, Matsui D, and Reider MJ, &ldquo;Assessment of the Palatability of Vehicles for Activated Charcoal in Pediatric Volunteers,&rdquo; <i>Pediatr Emerg Care</i>, 2002, 18(1):19-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/11862132/pubmed\" target=\"_blank\" id=\"11862132\">11862132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dorrington CL, Johnson DW, Brant R, &ldquo;The Frequency of Complications Associated With the Use of Multiple-Dose Activated Charcoal,&rdquo; <i>Ann Emerg Med</i>, 2003, 41(3):370-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/12605204/pubmed\" target=\"_blank\" id=\"12605204\">12605204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Francis RC, Schefold JC, Bercker S, et al, &quot;Acute Respiratory Failure After Aspiration of Activated Charcoal With Recurrent Deposition and Release From an Intrapulmonary Cavern,&quot; <i>Intensive Care Med</i>, 2009, 35(2):360-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/18795259/pubmed\" target=\"_blank\" id=\"18795259\">18795259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016; 24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gude AB, Hoegberg LC, Angelo HR, et al, &quot;Dose-Dependent Adsorptive Capacity of Activated Charcoal for Gastrointestinal Decontamination of a Simulated Paracetamol Overdose in Human Volunteers,&quot; <i>Basic Clin Pharmacol Toxicol</i>, 2010, 106(5):406-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/20002061/pubmed\" target=\"_blank\" id=\"20002061\">20002061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heard K, &quot;Gastrointestinal Decontamination,&quot; <i>Med Clin N Am</i>, 2005, 89(6):1067-78 (review).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/16227054/pubmed\" target=\"_blank\" id=\"16227054\">16227054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higgins T, Curry S, Brooks D, et al, &ldquo;Iatrogenic Administration of Propylene Glycol With Activated Charcoal,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2000, 38(5):529.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes C, Schauben J, and Hasan MY, &ldquo;An Evaluation of the Incidence of Emesis Following Oral Bolus Dosing vs Gradual Administration Regimens of Activated Charcoal,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1998, 36(5):431-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.<i> Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK and Kumar VV, &quot;Indications for Single-Dose Activated Charcoal Administration in Acute Overdose,&quot; <i>Curr Opin Crit Care</i>, 2011, 17(4):351-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/21716104/pubmed\" target=\"_blank\" id=\"21716104\">21716104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    J&uuml;rgens G, Hoegberg LC, and Graudal NA, &quot;The Effect of Activated Charcoal on Drug Exposure in Healthy Volunteers: A Meta-analysis,&quot; <i>Clin Pharmacol Ther</i>, 2009, 85(5):501-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/19194372/pubmed\" target=\"_blank\" id=\"19194372\">19194372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Justice HM, Knapp BJ, Pianalto DA, et al, &quot;Failure of Emergency Medical Services Providers to Administer Activated Charcoal Add to Emergency Delay,&quot; <i>Acad Emerg Med</i>, 2006, 13(5):S180.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juurlink DN. Activated charcoal for acute overdose: a reappraisal. <i>Br J Clin Pharmacol</i>. 2016;81(3):482-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/26409027/pubmed\" target=\"_blank\" id=\"26409027\">26409027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keyes C and DeTamble L, &ldquo;Prehospital Activated Charcoal: A Prospective Randomized Trial,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1999, 37(5):610.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krenzelok EP and Lush RM, &quot;Container Residue After the Administration of Aqueous Activated Charcoal Products,&quot; <i>Am J Emerg Med</i>, 1991, 9(2):144-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/1994942/pubmed\" target=\"_blank\" id=\"1994942\">1994942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merigian KS and Blaho KE, &ldquo;Single-Dose Oral Activated Charcoal in the Treatment of the Self-Poisoned Patient: A Prospective, Randomized, Controlled Trial,&rdquo; <i>Am J Ther</i>, 2002, 9(4):301-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/12115019/pubmed\" target=\"_blank\" id=\"12115019\">12115019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seger D, &ldquo;Single-Dose Activated Charcoal-Backup and Reassess,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2004, 42(1):101-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/15083946/pubmed\" target=\"_blank\" id=\"15083946\">15083946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vale JA, Krenzelok EP and Barceloux GD et al, American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists, &ldquo;Position Statement and Practice Guidelines on the Use of Multiple-Dose Activated Charcoal in the Treatment of Acute Poisoning,&rdquo; <i>Clin Toxicol</i>, 1999, 37(6):731-51.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity.<i> Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/activated-charcoal-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9237 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F149199\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F149200\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F149214\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F149202\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F149210\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F149203\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F149185\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F149172\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F149187\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F149186\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50015723\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F149220\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F149179\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149190\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F149176\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299010\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F149180\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F149196\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13657798\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13658389\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F149175\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F149189\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323056\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F149192\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9237|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=activated-charcoal-patient-drug-information\" class=\"drug drug_patient\">Activated charcoal: Patient drug information</a></li><li><a href=\"topic.htm?path=activated-charcoal-pediatric-drug-information\" class=\"drug drug_pediatric\">Activated charcoal: Pediatric drug information</a></li></ul></div></div>","javascript":null}